It was Jan. 24, 2020 when BioNTech CEO Uğur Şahin knew that Covid-19 was possible to turn into a international pandemic.
Though it was over a month and a half earlier than the World Health Organization formally declared a pandemic, Sahin met along with his spouse, BioNTech’s co-founder and chief medical officer Özlem Türeci. Together, they agreed to redirect many of the firm’s assets to creating a vaccine.
“He approached me and explained his thoughts and his his fears,” Türeci stated. “And it was immediately clear to both of us that the technology we had, and which we had already clinically developed, that could help to ensure a rapid response.”
Up till that time, BioNTech was primarily targeted on creating novel most cancers remedies. The firm was little-known internationally. But the founders have been assured within the potential of their mRNA know-how, which they knew may set off a highly effective immune response. BioNTech knew that to efficiently produce, check and manufacture a Covid vaccine on a international scale, it could want a larger companion. The firm already had a relationship with Pfizer, having labored with them since 2018 to develop an mRNA-based flu vaccine, which is in medical trials. So, BioNTech turned to them.
The corporations succeeded. In August, the Pfizer-BioNTech vaccine grew to become the primary to achieve full FDA approval.
Watch the video to study concerning the rise of BioNTech.